Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The invention relates to a pharmaceutical composition comprising between 10 and 30 g/l of fibrinogen, between 10 and 300 mM of arginine and between 10 and 300 mM of glutamate. In addition, the pH of the composition is between 6 and 8.

Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Abstract: The present invention relates to a method for the virus inactivation of a preparation of monoclonal antibodies, characterised in that it comprises a step of bringing the monoclonal antibody preparation into contact with a non-ionic detergent, said step being carried out while stirring in a disposable flexible pouch which can receive and contain the monoclonal antibody preparation.

Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Abstract: The invention relates to aptamers which specifically bind to fibrinogen and their use in the purification of said protein.

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

Abstract: In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

Abstract: The present application relates to a pharmaceutical composition for oral administration, comprising a monoclonal anti-tumor necrosis factor alpha antibody (TNF?) and at least one or more pharmaceutically acceptable excipients selected from the group comprising: a carboxymethyl-dextran, a chitosan, a cyclodextrin, or a combination of same, as well as the use of said composition in the treatment of inflammatory diseases or autoimmune diseases.

Abstract: The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.

Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal?1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.

Abstract: Disclosed is a method for purification of monoclonal antibodies or of a fusion protein between the Fc segment of an antibody and a second polypeptide, including a) an affinity chromatography step on a resin having as a matrix a crosslinked methacrylate polymer gel, on which the protein A is grafted, b) a viral inactivation step, c) a chromatography step exchanging cations on a resin having a crosslinked agarose gel matrix, on which sulfonate groups (—SO3—) are grafted using dextran-based spacer arms, d) a chromatography step exchanging anions on a hydrophilic membrane of polyethersulfone coated with a crosslinked polymer on which quaternary amine groups (Q) are grafted, and e) a nanofiltration step using a filter having an asymmetric polyethersulfone double membrane with a porosity of approximately 20 nm.

Abstract: The present invention concerns a protein comprising a mutated sequence of SEQ ID No. 1, said mutated sequence of SEQ ID No. 1 comprising at least one mutation A, A?, B, C or C?, in which: mutation A consists of substituting amino acids 43 to 52 of sequence SEQ ID No. 1 with a sequence chosen from DFLAEGLTPR (SEQ ID NO: 159), KATN*ATLSPR (SEQ ID NO: 160) and KATXATLSPR (SEQ ID NO: 161), mutation A? consists of substituting amino acids 47 to 52 of sequence SEQ ID No. 1 with a sequence chosen from TSKLTR (SEQ ID NO: 162), FNDFTR (SEQ ID NO: 163), LSSMTR (SEQ ID NO: 164), PPSLTR (SEQ ID NO: 165) and LSCGQR (SEQ ID NO: 166), mutation B consists of inserting a sequence chosen from DFLAEGLTPR (SEQ ID NO: 159), KATN*ATLSPR (SEQ ID NO: 160), KATXATLSPR (SEQ ID NO: 161), TSKLTR (SEQ ID NO: 162), FNDFTR (SEQ ID NO: 163), LSSMTR (SEQ ID NO: 164), PPSLTR (SEQ ID NO: 165) and LSCGQR (SEQ ID NO: 166), between amino acids 52 and 53 of sequence SEQ ID No.

Abstract: The present invention relates to an universal plasma, originating from a mixture of plasmas originating from donor individuals of blood groups A, B, AB and/or O and compatible with all the blood groups and the preparation process thereof.

Abstract: Disclosed is a composition including stable fibrinogen in liquid form.

Abstract: The invention relates to a bag (10) for storing a therapeutic solution, including at least one compartment (11) for receiving a solution and defined by a diaphragm (12). The bag further includes at least one appendage (13) forming an extension of the diaphragm (12) and comprising a writing area (14). The bag for storing a therapeutic solution according to the invention makes it possible to write on the bag with a reduced risk of contamination.

Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the proportion of Gal?1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.

Abstract: Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.

Abstract: The invention relates to aptamers which specifically bind to immunoglobulin G and their use in the purification of said protein.